Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in ...

Patients with low-grade upper tract urothelial carcinoma who achieved a complete response after receiving treatment with ...

Dr. Lee concluded his presentation discussing the comparative performance of UNFOLD AI, PSMA-PET, and mpMRI for prostate ...

The 2025 Western Section AUA annual meeting featured a kidney cancer session and a presentation by Jaxson Jeffery discussing the impact of neoadjuvant systemic therapy on tumor and tumor thrombus ...

Patients with bone-protecting agent use versus no bone-protecting agent had similar baseline characteristics: ...

The first 24 patients who received treatment with cretostimogene and were evaluated for high-grade recurrence-free survival and safety were evaluated. Kaplan-Meier estimates at 3- and 9-month ...

For Cohorts A and B, intravesical cretostimogene will be instilled in combination with DDM, an excipient that enhances adenoviral delivery, for six weekly doses during the induction phase, followed by ...

Cretostimogene grenadenorepvec, an oncolytic immunotherapy, selectively replicates in and lyses cancer cells with Rb-E2F pathway alterations, releasing antigens that initiate antitumor immune ...

Neeraj Agarwal discusses a Flatiron database analysis examining treatment intensification in metastatic hormone-sensitive prostate cancer. The study analyzed approximately 10,000 patients treated ...

Were you unable to attend LUGPA 2025 Annual Meeting? Get all of the groundbreaking research, new guidelines, ...

Radium-223 + Enzalutamide in mCRPC: Revisiting PEACE-3 Trial Data - Kristine Peregrino Lacuna PEACE-3 Trial: Enzalutamide Plus Radium-223 Improves Survival in mCRPC, Journal Club - Rashid Sayyid & ...

Tarcan T, Drake MJ, Igawa Y, et al. Can we predict whether a man with acute or chronic urinary retention will void after bladder outflow resistance reduction surgery? ICI-RS 2023. Neurourol Urodyn.